BLISSGVS — Bliss GVS Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapHigh Flyer

Annual income statement for Bliss GVS Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	7,475	7,516	7,702	8,097	9,271
Cost of Revenue
Gross Profit	3,482	3,431	3,777	3,847	5,020
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	7,200	6,529	6,752	7,125	7,990
Operating Profit	274	986	950	973	1,281
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	542	1,061	1,169	1,256	1,896
Provision for Income Taxes
Net Income After Taxes	231	767	816	903	1,347
Minority Interest
Net Income Before Extraordinary Items
Net Income	150	709	755	843	1,291
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	150	709	755	843	1,291
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	4.42	6.69	9.02	7.95	12.2
Dividends per Share